STANDARD BIOTLS (LAB)
(Delayed Data from NSDQ)
$2.29 USD
+0.18 (8.53%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $2.28 -0.01 (-0.44%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Standard BioTools Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 106 | 98 | 131 | 138 | 117 |
Cost Of Goods | 56 | 61 | 61 | 55 | 53 |
Gross Profit | 50 | 37 | 69 | 83 | 64 |
Selling & Adminstrative & Depr. & Amort Expenses | 127 | 153 | 137 | 134 | 116 |
Income After Depreciation & Amortization | -77 | -116 | -67 | -51 | -52 |
Non-Operating Income | 7 | -72 | 8 | 1 | -11 |
Interest Expense | 5 | 4 | 4 | 4 | 4 |
Pretax Income | -74 | -193 | -64 | -54 | -67 |
Income Taxes | 0 | -3 | -4 | -1 | -2 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -75 | -190 | -59 | -53 | -65 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -75 | -190 | -59 | -53 | -65 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -61 | -100 | -51 | -33 | -34 |
Depreciation & Amortization (Cash Flow) | 16 | 16 | 17 | 18 | 18 |
Income After Depreciation & Amortization | -77 | -116 | -67 | -51 | -52 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 79.16 | 78.31 | 75.88 | 72.04 | 66.78 |
Diluted EPS Before Non-Recurring Items | -0.58 | -1.23 | -0.56 | -0.50 | -0.53 |
Diluted Net EPS (GAAP) | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 |
Fiscal Year end for Standard BioTools Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 45.54 | 28.19 | 25.37 | 27.67 |
Cost Of Goods | NA | 21.35 | 14.62 | 14.21 | 14.06 |
Gross Profit | NA | 24.19 | 13.57 | 11.15 | 13.60 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 84.37 | 34.95 | 32.33 | 31.05 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -60.18 | -21.38 | -21.18 | -17.45 |
Non-Operating Income | NA | 28.15 | 2.55 | 1.45 | 1.84 |
Interest Expense | NA | 0.00 | 1.10 | 1.22 | 1.13 |
Pretax Income | NA | -32.03 | -19.94 | -20.95 | -16.74 |
Income Taxes | NA | 0.13 | -0.16 | 0.05 | 0.30 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -32.16 | -19.78 | -21.00 | -17.04 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -32.16 | -19.78 | -21.00 | -17.04 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 294.13 | 79.73 | 79.15 | 78.67 |
Diluted EPS Before Non-Recurring Items | NA | -0.26 | -0.12 | -0.19 | -0.18 |
Diluted Net EPS (GAAP) | NA | -0.27 | -0.24 | -0.27 | -0.22 |